As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

New data highlight liver-encoded delivery of immune modulators as a strategy to mitigate age-related immune dysfunction.

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own ...

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...